Will digital therapeutics complement or replace stimulant medications to address inattention and “silent” cognitive issues?

___ Akili Interactive: Digital pediatric ADHD therapeutic performs well with or without accompanying stimulant therapy (MobiHealth News): “Digital therapeutic company Akili Interactive has announced the first results of an open-label, multisite pediatric ADHD trial providing some patients with the company’s video game-like treatment alongside a stimulant medication. According to the company, both those who received the AKL-T01 therapy with (n = 130) or without (n = 76) accompanying stimulant medication saw significant improvements one month after baseline (p < .001) as measured by the trial’s primary outcome, ratings on the ADHD Impairment Rating Scale (IRS) reported by parents … While a full reporting of the study data is still being prepared for upcoming conferences or journal publication, Akili views these findings as evidence that AKL-T01 provides a benefit “independent of whether the children were on or off ADHD medication.” The Study: Akili Study of AKL-T01 With and Without Stimulant Medication in Children With ADHD Achieves Primary Efficacy Endpoint (press release): “Following our successful pivotal STARS-ADHD study of AKL-T01 as a potential treatment for inattention in children with ADHD not taking stimulant medications, understanding the benefit of our technology when used alongside ADHD medications has been a research priority for us. Importantly, parents see improvements in their children regardless of whether they are using the treatment alone or ...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Attention and ADD/ADHD Cognitive Neuroscience Health & Wellness Technology ADHD trial ADHD-medication Akili Interactive AKL-T01 cognitive issues digital therapeutic FDA clearance stimulant medication video game-like treatment Source Type: blogs